BioCryst Pharmaceuticals Inc (BCRX): Shareholders' Equity
-$119.15M
As of 2025-12-31
-$454.29M
As of 2026-06-30
| Period ended | Shareholders' Equity | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | -$119.15M | n/m | 2026-02-26, Balance as of period end |
| 2024-12-31 | -$475.93M | n/m | 2026-02-26, Balance as of period end |
| 2023-12-31 | -$455.53M | n/m | 2026-02-26, Balance as of period end |
| 2022-12-31 | -$294.60M | n/m | 2025-02-25, Balance as of period end |
| 2021-12-31 | -$106.99M | n/m | 2024-02-27, Balance as of period end |
| 2020-12-31 | -$19.26M | n/m | 2023-02-27, Balance as of period end |
| 2019-12-31 | $38.25M | -22.3% | 2022-02-28, Balance as of period end |
| 2018-12-31 | $49.23M | -41.2% | 2021-03-01, Balance as of period end |
| 2017-12-31 | $83.77M | n/m | 2020-03-13, Balance as of period end |
| 2016-12-31 | $1.58M | -96.7% | 2019-03-14, Balance as of period end |
| 2015-12-31 | $47.72M | -36.9% | 2018-03-12, Balance as of period end |
| 2014-12-31 | $75.64M | n/m | 2017-02-27, Balance as of period end |
| 2013-12-31 | -$1.13M | n/m | 2016-02-26, Balance as of period end |
| 2012-12-31 | -$454.0K | n/m | 2015-03-02, Balance as of period end |
| 2011-12-31 | $14.81M | -77.4% | 2014-03-10, Balance as of period end |
| 2010-12-31 | $65.50M | -24.1% | 2013-03-11, Balance as of period end |
| 2009-12-31 | $86.27M | n/a | 2012-03-06, Balance as of period end |
Shareholders' Equity at similar companies
| Company | Year ended | Shareholders' Equity | Change YoY |
|---|---|---|---|
| BioCryst Pharmaceuticals Inc (BCRX) | 2025-12-31 | -$119.15M | n/m |
| Repligen Corp (RGEN) | 2025-12-31 | $2.11B | +6.8% |
| Novavax Inc (NVAX) | 2025-12-31 | -$127.75M | n/m |
| Bio-Techne Corp (TECH) | 2026-06-30 | $2.11B | +9.9% |
| Halozyme Therapeutics, Inc. (HALO) | 2025-12-31 | $48.81M | -86.6% |
| ADMA Biologics, Inc. (ADMA) | 2025-12-31 | $477.32M | +36.8% |
| Tarsus Pharmaceuticals, Inc. (TARS) | 2025-12-31 | $343.43M | +53.0% |
| Immunocore Holdings plc (IMCR) | 2025-12-31 | $381.03M | +5.6% |
| Moderna, Inc. (MRNA) | 2025-12-31 | $8.65B | -20.6% |
Compare BCRX, RGEN, NVAX, TECH side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗